🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Longitudinal Neurocognitive, Psychosocial and Health-related Quality of Life Assessment in Advanced Cancer Survivors Treated With Immunotherapy and the Efficacy of Integrative Neurocognitive Remediation Therapy

RecruitingNAAges 18 Years - anyAllUniversitair Ziekenhuis Brussel
NCT05667857 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Since 2010, the field of immunotherapy has grown substantially, leading to a growing population of long-term cancer survivors treated with immunotherapy. Since cancer survivorship in immunotherapy is an emerging field, to date not much is known about psychosocial and neurocognitive survivorship-related issues in advanced cancer survivors treated with immunotherapy. Preliminary findings indicated significant psychosocial and cognitive problems in survivors of advanced melanoma persist after treatment with immunotherapy. The objective for this project is twofold. First, the investigators want to longitudinally identify survival-related problems in survivors of advanced cancer treated with immunotherapy. The second goal is to identify the efficacy of an Integrative Neuro-Cognitive Remediation Therapy (INCRT) program. The investigators will focus on the following outcomes: (1) Psychosocial c

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Non-intervention group: * Provision of written informed consent * Diagnosed with advanced cancer of any type * Initiated immunotherapy (Anti-PD1, Anti-PDL1, CTLA-4, …) at least one year ago * Have a confirmed normalization on whole-body 18F-FDG PET * English, Dutch or French-speaking 2. Integrative neurocognitive remediation therapy group: * Provision of written informed consent * Objective cognitive impairment and/or subjective cognitive complaints * Confirmed normalization on whole-body 18F-FDG PET for patients (cohort 1) * Disease-free (cohort 2) or no active disease for patients with CNS tumors (cohort 3) * Having received a cancer therapy of any kind * Having ended cancer treatment (immunotherapy, chemotherapy, radiotherapy, surgery, …) with an exception of ongoing adjuvant hormone therapy * Dutch or French speaking Exclusion Criteria: * severe co-morbid non cancer-related psychiatric disorders such as psychosis, obsessive compulsive disorders, eating disorders etc., patients with cognitive impairment related to dementia, and patients that are physically or mentally not able to fill in the questionnaires
💊

What it tests

  • Integrative neurocognitive remediation therapy
📍

Where

2 sites
University Hospital Brugmann
Brussels, Belgium
Universitair Ziekenhuis Brussel
Brussels, Belgium
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy